| Q46861635 | A bladder-cooling reflex in the anaesthetised guinea-pig: a model of the positive clinical ice-water test |
| Q35172477 | After a decade of intravesical vanilloid therapy: still more questions than answers |
| Q34635410 | Bladder afferents and their role in the overactive bladder |
| Q44535405 | Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. |
| Q30832054 | Bladder sensory desensitization decreases urinary urgency. |
| Q38008697 | Botulinum toxin injection for lower urinary tract dysfunction |
| Q38193083 | Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis |
| Q42474245 | Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. |
| Q33242977 | Characterization of the purinergic receptor subtype on guinea-pig suburothelial myofibroblasts |
| Q89705017 | Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis |
| Q66829269 | Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics |
| Q35184515 | Contractile responses of urinary bladder in an experimental model of chronic renal failure |
| Q35687973 | Control of bladder function by peripheral nerves: avenues for novel drug targets |
| Q38564108 | Current and potential urological applications of botulinum toxin A. |
| Q35543206 | Defining protein expression in the urothelium: a problem of more than transitional interest |
| Q46855828 | Detrusor overactivity induced by intravesical application of adenosine 5'-triphosphate under different delivery conditions in rats |
| Q83947318 | Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome |
| Q42026571 | Differential localizations of the transient receptor potential channels TRPV4 and TRPV1 in the mouse urinary bladder |
| Q46616706 | Distribution of the vanilloid (capsaicin) receptor type 1 in the human stomach |
| Q51550465 | Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin‐sensitivity |
| Q42439930 | Effects of resiniferatoxin desensitization of capsaicin-sensitive afferents on detrusor over-activity induced by intravesical capsaicin, acetic acid or ATP in conscious rats |
| Q44756647 | Endothelial nitric oxide synthase expression in neurogenic urinary bladders treated with intravesical resiniferatoxin |
| Q80298181 | Etiology, pathogenesis, and diagnosis of interstitial cystitis |
| Q46662778 | Expression and electrophysiological characteristics of P2X3 receptors in interstitial cells of Cajal in rats with partial bladder outlet obstruction |
| Q47760337 | Expression of P2X3 purinoceptors in suburothelial myofibroblasts of the normal human urinary bladder |
| Q35908570 | Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome |
| Q37942411 | From urgency to frequency: facts and controversies of TRPs in the lower urinary tract. |
| Q30409620 | In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization |
| Q35009629 | Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy |
| Q37211785 | Inflammatory pain: the cellular basis of heat hyperalgesia. |
| Q35545736 | Integrated control of lower urinary tract--clinical perspective |
| Q44951596 | Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders |
| Q35646860 | Intravesical therapy options for neurogenic detrusor overactivity |
| Q89834810 | Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders |
| Q35687993 | Mechanisms involved in new therapies for overactive bladder. |
| Q36445282 | Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction |
| Q36566845 | Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents |
| Q35687975 | New pharmacologic targets for the treatment of the overactive bladder: an update |
| Q58122186 | Novobiocin, a Newly Found TRPV1 Inhibitor, Attenuates the Expression of TRPV1 in Rat Intestine and Intestinal Epithelial Cell Line IEC-6 |
| Q39248588 | P2X3 antagonists: novel therapeutics for afferent sensitization and chronic pain |
| Q39249530 | P2X3 receptor-mediated visceral hyperalgesia and neuronal sensitization following exposure to PTSD-like stress in the dorsal root ganglia of rats |
| Q36728925 | Peripheral and central mechanisms of visceral sensitization in man. |
| Q35031200 | Pharmacologic perspective on the physiology of the lower urinary tract |
| Q28237411 | Pharmacology of P2X channels |
| Q38671606 | Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome |
| Q38210145 | Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis |
| Q35737565 | Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome |
| Q37148393 | Purinergic signaling in the lumen of a normal nephron and in remodeled PKD encapsulated cysts |
| Q37620260 | Purinergic signalling in the urinary tract in health and disease |
| Q35545723 | Purinoceptors as therapeutic targets for lower urinary tract dysfunction |
| Q53655799 | Reduction of urgency severity is the most important factor in the subjective therapeutic outcome of intravesical onabotulinumtoxinA injection for overactive bladder. |
| Q33562153 | TRP channels in lower urinary tract dysfunction |
| Q36487773 | TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. |
| Q30434994 | TRPV1: A Potential Drug Target for Treating Various Diseases |
| Q90457679 | The Urothelium: Life in a Liquid Environment |
| Q53416468 | The influence of intravesical administration of resiniferatoxin (RTX) on the chemical coding of sympathetic chain ganglia (SChG) neurons supplying the porcine urinary bladder. |
| Q90394415 | Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside |
| Q38233692 | Transient receptor potential channel modulators as pharmacological treatments for lower urinary tract symptoms (LUTS): myth or reality? |
| Q37682186 | Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder |
| Q30440958 | Urothelial signaling |
| Q33949424 | Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. |